XML 158 R144.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-based compensation plan - Phantom shares plan ("PS") and Restricted Shares (Details)
 12 Months Ended
Dec. 31, 2024
BRL (R$)
shares
R$ / shares
shares
Dec. 31, 2023
BRL (R$)
shares
R$ / shares
Dec. 31, 2022
BRL (R$)
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Share-based compensation plans | R$ R$ 361,974,000 R$ 268,489,000  
Time to calculate the average price of shares based on recent trading sessions 90 days    
PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 10,096,497 9,728,425  
Granted during of the year 2,981,547    
Cancelled 923,167    
Exercised (1) 1,690,308    
Available for completion 458,664    
Restricted stock, year one 3,591,140    
Restricted stock, year two 3,049,039    
Restricted stock, year three 2,793,223    
Restricted stock, year four 204,431    
Share-based compensation plans | R$ R$ 361,974,000 R$ 268,489,000 R$ 162,117,000
Stock options granted (Note 23) | R$ 173,486,000 154,318,000  
Decrease Provision Share Based Payment | R$ R$ (80,001,000) R$ (47,946,000)  
Phantom Share Units Psus      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Phantom Share Units Psus | R$ / shares R$ 42.36 R$ 58.07  
Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 2,980,111 592,749  
Granted during of the year 3,392,475    
Exercised (1) 1,005,113    
Restricted stock, year one 453,265    
Restricted stock, year two 489,074    
Restricted stock, year three 417,772    
Restricted stock, year four 1,620,000    
Share-based compensation plans | R$ R$ 60,226,000 R$ 26,744,000 R$ 18,425,000
Stock options granted (Note 23) | R$ 81,276,000 8,319,000  
Decrease Provision Share Based Payment | R$ R$ (47,794,000)  
Grant Year 2019 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 42.81  
Number of other equity instruments outstanding in share-based payment arrangement 39,461  
Granted during of the year 903    
Cancelled    
Exercised (1) 40,364    
Available for completion    
Restricted stock, year one    
Restricted stock, year two    
Restricted stock, year three    
Restricted stock, year four    
Grant Year 2020 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 38.36  
Number of other equity instruments outstanding in share-based payment arrangement 33,384 984,160  
Granted during of the year 22,525    
Cancelled 204,963    
Exercised (1) 768,338    
Available for completion 33,384    
Restricted stock, year one    
Restricted stock, year two    
Restricted stock, year three    
Restricted stock, year four    
Grant Year 2021 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 62.15  
Number of other equity instruments outstanding in share-based payment arrangement 874,480 1,724,020  
Granted during of the year 39,387    
Cancelled 66,231    
Exercised (1) 822,696    
Available for completion 425,280    
Restricted stock, year one 449,200    
Restricted stock, year two    
Restricted stock, year three    
Restricted stock, year four    
Grant Year 2021 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 51.70  
Number of other equity instruments outstanding in share-based payment arrangement 111,685  
Granted during of the year 2,559    
Exercised (1) 114,244    
Restricted stock, year one    
Restricted stock, year two    
Restricted stock, year three    
Restricted stock, year four    
Grant Year 2022 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 57.54  
Number of other equity instruments outstanding in share-based payment arrangement 3,461,437 3,686,722  
Granted during of the year 84,207    
Cancelled 286,478    
Exercised (1) 23,014    
Available for completion    
Restricted stock, year one 3,113,607    
Restricted stock, year two 324,611    
Restricted stock, year three 23,219    
Restricted stock, year four    
Grant Year 2022 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 53.81  
Number of other equity instruments outstanding in share-based payment arrangement 115,800 113,161  
Granted during of the year 2,639    
Exercised (1)    
Restricted stock, year one 115,800    
Restricted stock, year two    
Restricted stock, year three    
Restricted stock, year four    
Grant Year 2023 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 48.79  
Number of other equity instruments outstanding in share-based payment arrangement 3,052,179 3,294,062  
Granted during of the year 74,647    
Cancelled 283,548    
Exercised (1) 32,982    
Available for completion    
Restricted stock, year one 28,333    
Restricted stock, year two 2,721,535    
Restricted stock, year three 302,311    
Restricted stock, year four    
Grant Year 2023 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 51.45  
Number of other equity instruments outstanding in share-based payment arrangement 383,568 367,903  
Granted during of the year 15,665    
Exercised (1)    
Restricted stock, year one    
Restricted stock, year two 268,534    
Restricted stock, year three 115,034    
Restricted stock, year four    
Grant Year 2024 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 56.52  
Number of other equity instruments outstanding in share-based payment arrangement 2,675,017  
Granted during of the year 2,759,878    
Cancelled 81,947    
Exercised (1) 2,914    
Available for completion    
Restricted stock, year one    
Restricted stock, year two 2,893    
Restricted stock, year three 2,467,693    
Restricted stock, year four 204,431    
Grant Year 2024 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 55.27  
Number of other equity instruments outstanding in share-based payment arrangement 2,480,743  
Granted during of the year 3,371,612    
Exercised (1) 890,869    
Restricted stock, year one 337,465    
Restricted stock, year two 220,540    
Restricted stock, year three 302,738    
Restricted stock, year four 1,620,000    
SAR and PLUS | Top of range [member] | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Share-based compensation arrangement by share-based payment award, award vesting period 5 years    
SAR and PLUS | Top of range [member] | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Share-based compensation arrangement by share-based payment award, award vesting period 5 years